e.g. mhealth
Search Results (1 to 10 of 11 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 4 Journal of Medical Internet Research
- 2 JMIR Research Protocols
- 2 JMIR mHealth and uHealth
- 1 JMIR Cardio
- 1 JMIR Formative Research
- 1 JMIR Medical Informatics
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Public Health and Surveillance
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
With a usage history spanning over 60 years, warfarin is currently the most widely used anticoagulant prescription drug for preventing thrombosis after heart valve surgery, orthopedic surgery, atrial fibrillation, and varicose veins of the lower extremities, as well as systemic embolism, pulmonary embolism, and venous thromboembolism [1]. Daily management of warfarin is highly correlated with clinical outcomes.
J Med Internet Res 2024;26:e46319
Download Citation: END BibTex RIS
Warfarin is a commonly prescribed oral anticoagulant for patients who have undergone cardiac surgery and remains the only guideline-endorsed anticoagulant for patients with mechanical heart valves. However, considerable interindividual variability exists in the response to warfarin, with patient age, BMI, concomitant medications, and genetic status imparting considerable influence on warfarin maintenance dose requirements [1-5].
JMIR Cardio 2023;7:e47262
Download Citation: END BibTex RIS
We will collaborate with their treating clinicians and calculate a warfarin initiation dose using the relevant algorithm.
Day 0 is considered the first day that warfarin is taken. We recruited participant up to 7 days before and no more than 1 day after warfarin was initiated, meaning some individuals may have taken a single warfarin dose. We will use a paper-based dosing table, using dose formulations currently available, which has been developed for implementation (Multimedia Appendix 1).
JMIR Res Protoc 2023;12:e46710
Download Citation: END BibTex RIS
Telemedicine-Based Management of Oral Anticoagulation Therapy: Systematic Review and Meta-analysis
Even in recent clinical trials of DOAC versus warfarin, TTR in control groups varied widely across various geographical regions [47], reaching values as low as 36% in India. Hence, e Health implementation may positively impact the quality of anticoagulation, especially in underserved regions.
The complexity and potential hazards associated with OAT, especially VKAs, make it a still underused therapy, and anticipation of difficulty in management is a frequent barrier to an adequate prescription of OAT [48].
J Med Internet Res 2023;25:e45922
Download Citation: END BibTex RIS
Approximately 8 million people in the United States received anticoagulants, including warfarin, in 2019 [1]. Warfarin is well known for having a multitude of drug-drug interactions (DDIs), with many avoided through health care provider awareness. However, studies found that up to 24% of people taking warfarin also received a prescription for nonsteroidal anti-inflammatory drugs (NSAIDs), and almost 50% of patients on warfarin have some form of ongoing pain [2,3].
JMIR Form Res 2022;6(10):e40018
Download Citation: END BibTex RIS
Warfarin, as an anticoagulation drug, is widely used in the prevention of various thromboembolic events [6], but it is not easy to control due to the narrow therapeutic range and patients’ heterogeneity. Therefore, the dosage of warfarin needs to be adjusted accordingly by the international normalized ratio (INR) [7,8].
J Med Internet Res 2021;23(8):e29529
Download Citation: END BibTex RIS
Without proper adjustment, excessive warfarin may cause bleeding, and inadequate warfarin doses may cause thrombosis and possible death [3]. This represents a costly use of medical resources and is physically and psychologically traumatic to patients and their families [4].
Warfarin dose adjustment is usually performed at hospital clinics. For patients living in rural areas, adjustment of warfarin dosages requires transportation, accommodation, and time.
JMIR Mhealth Uhealth 2021;9(3):e23332
Download Citation: END BibTex RIS
Oral anticoagulants (OACs) have been used for decades, especially warfarin, which has been in use since the 1950s. Until recently warfarin has been a fundamental drug in clinical anticoagulant therapy, and although the results of two previously published meta-analyses of atrial fibrillation suggested that novel OACs are not inferior to warfarin in terms of safety and efficacy [1,2], warfarin has the advantage of being inexpensive and having a wide range of indications.
J Med Internet Res 2020;22(7):e18386
Download Citation: END BibTex RIS
Warfarin is one of the most commonly prescribed medications in the United States, with more than 20 million Americans taking warfarin anticoagulation therapy to prevent the formation of blood clots. As one of the most common culprits of adverse drug events (ADEs) in outpatient settings [1], warfarin dosing must be individualized to be effective; overdosing of warfarin can cause serious bleeding complications, whereas underdosing does not provide adequate protection against thromboembolism.
JMIR Res Protoc 2020;9(1):e13835
Download Citation: END BibTex RIS
In recent years, the NOACs (ie, dabigatran, rivaroxaban, and apixaban) have been launched and suggested as alternatives to warfarin. Compared with warfarin, NOACs demonstrated similar or better stroke prevention effects and similar or lower risks of bleeding in clinical trials [25-27]. Moreover, the NOACs exhibit fewer drug-food or drug-drug interactions and do not require regular monitoring.
JMIR Med Inform 2019;7(3):e13329
Download Citation: END BibTex RIS